The inhibition of the T-cell immunoglobulin and mucin domain 3 (Tim3) pathway enhances the efficacy of tumor vaccine

Biochemical and Biophysical Research Communications

Volumn 402, Issue 1, 2010, Pages 88-93

  Lee, Mi Jin ^a   Woo, Min Yeong ^a   Heo, Yoo Mi ^a   Kim, Jung Sik ^a   Kwon, Myung Hee ^a   Kim, Kyongmin ^a   Park, Sun ^a  

^a Ajou University School of Medicine   (South Korea)

Author keywords

Immunotherapy; Tim3; Tim3 inhibition; Tregs; Tumor vaccine

Indexed keywords

FLUOROURACIL; IMMUNOGLOBULIN; MUCIN; TRANSCRIPTION FACTOR FOXP3; TUMOR VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CD4+ CD25+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG EFFICACY; LEWIS CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; T LYMPHOCYTE; TUMOR GROWTH;

ANIMALS; ANTIGENS, CD4; CANCER VACCINES; CARCINOMA, LEWIS LUNG; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; T-LYMPHOCYTES, REGULATORY; TUMOR SUPPRESSOR PROTEINS;

MUS;

EID: 78049264841     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.09.121     Document Type: Article

References (34)

1. Dougan M., Dranoff G. Immune therapy for cancer. Annu. Rev. Immunol. 2009, 27:83-117.
2. Hodi F.S., Butler M., Oble D.A., et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc. Natl. Acad. Sci. USA 2008, 105:3005-3010.
3. Hodi F.S., Mihm M.C., Soiffer R.J., et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc. Natl. Acad. Sci. USA 2003, 100:4712-4717.
4. Curiel T.J. Regulatory T cells and treatment of cancer. Curr. Opin. Immunol. 2008, 20:241-246.
5. + T cells in B-cell non-Hodgkin lymphoma. Blood 2006, 107:3639-3646.
6. Dannull J., Su Z., Rizzieri D., et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J. Clin. Invest. 2005, 115:3623-3633.
7. Swann J.B., Smyth M.J. Immune surveillance of tumors. J. Clin. Invest. 2007, 117:1137-1146.
8. Sabatos C.A., Chakravarti S., Cha E., et al. Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance. Nat. Immunol. 2003, 4:1102-1110.
9. Sanchez-Fueyo A., Tian J., Picarella D., et al. Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance. Nat. Immunol. 2003, 4:1093-1101.
10. Monney L., Sabatos C.A., Gaglia J.L., et al. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature 2002, 415:536-541.
11. + T cells in murine acute graft-versus-host disease. J. Immunol. 2006, 177:4281-4287.
12. Nakayama M., Akiba H., Takeda K., et al. Tim-3 mediates phagocytosis of apoptotic cells and cross-presentation. Blood 2009, 113:3821-3830.
13. Zhu C., Anderson A.C., Schubart A., et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat. Immunol. 2005, 6:1245-1252.
14. DeKruyff R.H., Bu X., Ballesteros A., et al. and mucin-3 allelic variants differentially recognize phosphatidylserine and mediate phagocytosis of apoptotic cells. J. Immunol. 2010, 184:1918-1930.
15. Seki M., Oomizu S., Sakata K.M., et al. Galectin-9 suppresses the generation of Th17, promotes the induction of regulatory T cells, and regulates experimental autoimmune arthritis. Clin. Immunol. 2008, 127:78-88.
16. Anderson A.C., Anderson D.E., Bregoli L., et al. Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells. Science 2007, 318:1141-1143.
17. Lee M.J., Heo Y.M., Hong S.H., et al. The binding properties of glycosylated and non-glycosylated Tim-3 molecules on CD4CD25 T Cells. Immune Netw. 2009, 9:58-63.
18. Chen M.L., Pittet M.J., Gorelik L., et al. Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo. Proc. Natl. Acad. Sci. USA 2005, 102:419-424.
19. Woo E.Y., Chu C.S., Goletz T.J., et al. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. 2001, 61:4766-4772.
20. + regulatory T cells. Immunobiology 2009, 214:342-349.
21. + T cells and enhances antitumor immunity via galectin-9-Tim-3 interactions. J. Immunol. 2008, 181:7660-7669.
22. Klibi J., Niki T., Riedel A., et al. Blood diffusion and Th1-suppressive effects of galectin-9-containing exosomes released by Epstein-Barr virus-infected nasopharyngeal carcinoma cells. Blood 2009, 113:1957-1966.
23. Huang X., Bai X., Cao Y., et al. Lymphoma endothelium preferentially expresses Tim-3 and facilitates the progression of lymphoma by mediating immune evasion. J. Exp. Med. 2010, 207:505-520.
24. Wu F.H., Yuan Y., Li D., et al. Endothelial cell-expressed Tim-3 facilitates metastasis of melanoma cells by activating the NF-kappaB pathway. Oncol. Rep. 2010, 24:693-699.
25. Ju Y., Hou N., Meng J., et al. T cell immunoglobulin- and mucin-domain-containing molecule-3 (Tim-3) mediates natural killer cell suppression in chronic hepatitis B. J. Hepatol. 2010, 52:322-329.
26. + T cells. J. Virol. 2009, 83:9122-9130.
27. + myeloid cells. J. Immunol. 2010, 185:1383-1392.
28. Yang Z.Z., Novak A.J., Ziesmer S.C., et al. Attenuation of CD8(+) T-cell function by CD4(+)CD25(+) regulatory T cells in B-cell non-Hodgkin's lymphoma. Cancer Res. 2006, 66:10145-10152.
29. Almand B., Clark J.I., Nikitina E., et al. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J. Immunol. 2001, 166:678-689.
30. + myeloid cells tip the balance of immune protection to tumor promotion in the premetastatic lung. Cancer Res. 2010, 70:6139-6149.
31. + myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin. Cancer Res. 2005, 11:6713-6721.
32. Gabrilovich D.I., Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 2009, 9:162-174.
33. Vincent J., Mignot G., Chalmin F., et al. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. 2010, 70:3052-3061.
34. Jinushi M., Nakazaki Y., Dougan M., et al. MFG-E8-mediated uptake of apoptotic cells by APCs links the pro- and antiinflammatory activities of GM-CSF. J. Clin. Invest. 2007, 117:1902-1913.